Up-to-date List of Dexedrine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Dexedrine Medical Research Studies

RankStatusStudy
1 Recruiting A Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Conditions: Healthy Volunteers;   Drug Users
Interventions: Drug: EB-1020 400 mg;   Drug: EB-1020 800 mg;   Drug: d-amphetamine 20 mg;   Drug: d-amphetamine 40 mg;   Drug: Placebo
Outcome Measures: Maximum effect (Emax) on Drug Liking visual analog scale (VAS);   Drug Liking VAS (minimum effect [Emin] and time-averaged area under the effect curve to 12 hours after study drug administration [TA_AUE]);   Overall Drug Liking VAS (Emax/Emin);   Take Drug Again VAS (Emax);   High VAS (Emax and TA_AUE);   Good Effects VAS (Emax and TA_AUE);   Bad Effects VAS (Emax and TA_AUE);   Nausea VAS (Emax and TA_AUE);   ARCI-A scale (Emax and TA_AUE);   ARCI-BG scale (Emax and TA_AUE);   Alertness/Drowsiness VAS (Emax and TA_AUE);   Agitation/Relaxation VAS (Emax and TA_AUE);   Any Effects VAS (Emax and TA_AUE);   Drug Similarity VAS (score at 12 hours after study drug administration);   Safety and tolerability of EB-1020 as assessed by AEs;   Safety and tolerability of EB-1020 by laboratory assessments;   Safety and tolerability of EB-1020 as assessed by 12-lead ECGs;   Safety and tolerability of EB-1020 as assessed by vital signs
2 Recruiting Stimulant Enhancement of Well-Being Therapy for Depression
Condition: Major Depressive Disorder
Interventions: Drug: Amphetamine-dextroamphetamine (AMPH);   Drug: Placebo;   Behavioral: Well-being therapy
Outcome Measures: Change in Hamilton-Depression Rating Scale(SIGH-D)-17 items;   Change in Hamilton-Depression Rating Scale(SIGH-D)-31 item;   Change in Psychological Well-being Scale (PWB);   Change in the Snaith-Hamilton Pleasure Scale (SHAPS);   Change in Behavioral inhibition/activation scale (BIS/BAS);   Change in Positive and Negative Affective Scale (PANAS);   Change in functioning on Short Form-12(SF-12)
3 Unknown  Substance Abuse Pre-Treatment Screening Study
Conditions: Cocaine Abuse;   Cocaine Dependence;   Opiate Dependence;   Alcohol Dependence;   Substance Abuse
Interventions: Drug: modafinil;   Drug: d-amphetamine;   Drug: L-Dopa;   Drug: Naltrexone
Outcome Measures: Urine Toxicology;   Demographics
4 Recruiting Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Behavioral: Academic and Organization skills;   Behavioral: Parent Training;   Behavioral: Social Skills Training;   Drug: Long-acting stimulant
Outcome Measures: Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version);   Social skills (measured via Parent and Teacher Social Skills Rating Scale);   Academic achievement (measured via Wechsler Individual Achievement Test (WIAT));   Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL));   Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS));   Overall functioning (measured via the Clinical Global Impression Scale (CGI))
5 Recruiting Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Valproate;   Drug: Risperidone;   Drug: Placebo;   Drug: Stimulant medication;   Behavioral: Behavioral family counseling
Outcome Measures: Aggressive behavior;   ADHD symptoms
6 Recruiting Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
Conditions: Attention Deficit Hyperactivity Disorder (ADHD);   Deficient Emotional Self-Regulation (DESR)
Interventions: Drug: ADHD Medication;   Drug: Omega-3 Fatty Acids
Outcome Measures: Efficacy assessed by mean change from baseline to endpoint on the BRIEF-A Emotional Control scale;   Efficacy measured by mean change from baseline to endpoint on AISRS total score;   Efficacy measured by mean change from baseline to endpoint on CGI;   Efficacy measured by mean change from baseline to endpoint on BRIEF-A subscales;   Efficacy measured by mean change from baseline to endpoint on GAF
7 Recruiting IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents
Conditions: ADHD;   HIV
Intervention:
Outcome Measure: Estimation of steady-state oral clearance (Cl/F) for each psychiatric study medication is the primary outcome.
8 Recruiting Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
Condition: Cocaine Dependence
Intervention: Drug: Lisdexamfetamine
Outcome Measures: the maximum total lisdexamfetamine dose achieved;   Change in Cocaine use;   Change in Cocaine craving
9 Not yet recruiting Event Rate and Effects of Stimulants in ADHD
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LDX.;   Drug: sugar pill;   Device: computer task (Go/No-Go task);   Device: EEG;   Device: pupil size measurements (by using eye tracking)
Outcome Measures: Performance data (by using computerized Go-No Go task);   psychophysiological data
10 Recruiting Efficacy of Intuniv Extended Release as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Guanfacine extended release;   Drug: Placebo
Outcome Measures: To evaluate the effect of adjunctive INTUNIV extended release treatment on executive function as assessed by the BRIEF-parent questionnaires;   To evaluate the effect of adjunctive INTUNIV extended release treatment on quality of life as assessed by the KINDL®-child and KINDL®-parent questionnaires.;   To examine the congruency of the perceived effect of treatment on EF and quality of life from the perspective of the subject, parent, and teacher.;   To evaluate the effect of adjunct therapy on ADHD symptom control as assessed by the ADHD Rating Scale (ADHD-RS-IV) and Clinical Global Impression (CGI) of Severity (CGI-S) and of Improvement (CGI-I) questionnaires.;   To compare the percentage of subjects experiencing suicidal ideation, suicidal behaviour and self-injurious behaviour without suicidal intent and incident of Serious Adverse Events in each treatment arm
11 Recruiting Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Conditions: Intermittent Explosive Disorder;   Childhood Aggression;   Oppositional Defiant Disorder;   Attention Deficit Disorder
Interventions: Behavioral: Parent Management Training;   Other: Placebo;   Drug: Intuniv
Outcome Measures: Responder vs Non-Responder Assessment Form;   Percent change in score on the Attention Deficit Hyperactivity Disorder [ADHD] Rating Scale;   Percent change in the Modified Overt Aggression Scale;   Percent Change in the Score on Hostility Subscale of the Hopkins Symptom Checklist
12 Recruiting Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects
Condition: Attention Deficit Hyperactivity Disorder (ADHD)
Intervention:
Outcome Measures: The height velocity standard deviation score;   Changes in growth;   Changes to the cardiovascular system;   Effects on Psychiatric state;   Changes in neurological state
13 Recruiting Effects of Hallucinogens and Other Drugs on Mood and Performance
Condition: Healthy
Intervention: Drug: Hallucinogens and psychoactive substances
Outcome Measures: Rating of "Drug Liking" on the End of Day Questionnaire;   Hallucinogen Rating Scale
14 Not yet recruiting Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
Condition: Methamphetamine Dependence
Interventions: Drug: Lisdexamfetamine;   Drug: Placebo
Outcome Measure: Percentage of participants that relapse to methamphetamine use.
15 Recruiting Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Condition: Severe Mood Dysregulation
Interventions: Drug: lisdexamfetamine;   Drug: Placebo;   Drug: fluoxetine
Outcome Measures: Clinical Global Impression-Improvement-Severe Mood Dysregulation;   Pediatric Anxiety Rating Scale (PARS);   Children's Depression Rating Scale;   ADHD-IV Rating Scale;   ADHD IV Rating Scale;   Columbia Suicide Severity Scales;   Barnes Akathisia Scale;   Children's Affective Lability Scale;   Physical Symptom Checklist;   Revised Modified Overt Aggression Scale;   Screen for Children's Affective Reactivity;   Affective Reactivity Index
16 Recruiting Examining Emotional Lability in Patients With Attention Deficit Hyperactivity Disorder (ADHD): An fMRI Study
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine;   Drug: Placebo
Outcome Measure: Emotional lability as determined by fMRI signal
17 Not yet recruiting ADHD Medication and Predictors of Treatment Outcome
Condition: Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions: Drug: methylphenidate medication;   Drug: atomoxetine medication;   Drug: lisdexamphetamine medication
Outcome Measures: change in SNAP-IV Teacher and Parent rating scale (Swanson, Nolan and Pelham ADHD Rating Scale);   change in P-SEC (Pediatric Side Effects Checklist);   change in CGI-S (Clinical Global Impression- of Severity);   change in C-GAS (Children´s global assessment scale);   change in SNAP-IV Teacher and Parent rating scale;   change in Spence Children's Anxiety Scale (SCAS);   change in heart rate;   change in systolic blood pressure;   change in diastolic blood pressure;   change in weight z-score;   change in height z-score
18 Recruiting Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Condition: Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders
Interventions: Drug: Lisdexamfetamine Dimesylate;   Drug: placebo
Outcome Measures: ADHD Rating Scale;   Clinical Global Impression - Improvement Scale (CGI-I);   Yale Global Tic Severity Scale (YGTSS);   the Overall Anxiety Severity and Impairment Scale (OASIS);   The Weiss Functional Impairment Rating Scale-Self Report (WFIRS-S);   Barkley Adult ADHD Rating Scale--IV(BAARS-IV);   Revised Padua Inventory;   The Panic and Agoraphobia Scale (PAS);   Quick Inventory of Depressive Symptoms (QID-SR-16);   The Sheehan Disability Scale (SDS);   GAD-7;   Social Phobia Inventory (SPIN);   The Life Events Questionnaire (LEQ);   The Pittsburgh Sleep Quality Index (PSQI);   Clinical Global Impression - Severity (CGI-S)
19 Recruiting Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Condition: Binge Eating Disorder
Interventions: Drug: Lisdexamfetamine dimesylate;   Other: Placebo
Outcome Measures: Time to Relapse of Binge Eating;   Number of Binge-Eating Days Per Week;   Clinical Global Impression-Severity of Illness (CGI-S) Scale;   Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE);   EuroQuol Questionnaire (EQ-5D-5L);   Columbia-Suicide Severity Rating Scale (C-SSRS);   Amphetamine Cessation Symptom Assessment (ACSA)
20 Unknown  Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Drug: Lisdexamfetamine dimesylate
Outcome Measure: ADHD rating scale IV

These studies may lead to new treatments and are adding insight into Dexedrine etiology and treatment.

A major focus of Dexedrine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Dexedrine

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us